Publication date: Jun 12, 2019
The treatment of advanced melanoma has been dramatically improved by the introduction of immune checkpoint inhibitors (ICIs). Previous studies indicated that blockading anti-PD-1 antibodies is more effective than anti-CTLA-4 antibodies . However, the response to anti-PD-1 antibodies in cases of acral lentiginous melanoma (ALM) and mucosal melanoma (MCM), the common melanoma types in Asians, is poorer than in cutaneous melanoma (CM), the major type in Caucasians . Since PD-L1 expression is an important biomarker for predicting tumor responses to anti-PD-1 antibodies, we speculated that the low responses to anti-PD-1 antibodies in ALM and MCM may be due to lower PD-L1 expression compared to CM. This article is protected by copyright. All rights reserved.
Nakamura, Y., Ishitsuk, Y., Tanak, R., Okiyama, N., Saito, A., Watanabe, R., and Fujisawa, Y. Acral lentiginous melanoma and mucosal melanoma expressed less programmed-death 1 ligand than cutaneous melanoma: a retrospective study of 73 Japanese melanoma patients. 22942. 2019 J Eur Acad Dermatol Venereol.
|disease||DOID||Acral lentiginous melanoma|
- Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma.
- Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study.